Pages that link to "Q33329329"
The following pages link to Pre-irradiation carboplatin and etoposide and accelerated hyperfractionated radiation therapy in patients with high-grade astrocytomas: a phase II study (Q33329329):
Displaying 13 items.
- Prospective single-arm study of 72 Gy hyperfractionated radiation therapy and combination chemotherapy for anaplastic astrocytomas (Q33315042) (← links)
- Concurrent accelerated hyperfractionated radiation therapy and carboplatin/etoposide in patients with malignant glioma: long-term results of a phase II study (Q33337565) (← links)
- Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme (Q33366011) (← links)
- Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials (Q33586021) (← links)
- Pharmacotherapy of malignant astrocytomas of children and adults: current strategies and future trends (Q34387557) (← links)
- Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933. (Q36325851) (← links)
- The metabolic epicenter of supratentorial gliomas: a 1H-MRSI study. (Q43229988) (← links)
- Safety of thrice-daily hyperfractionated radiation and BCNU for high-grade gliomas (Q43742085) (← links)
- Prospective trial of radiotherapy after hyperbaric oxygenation with chemotherapy for high-grade gliomas (Q44448475) (← links)
- The Clinic of Neurosurgery at the Clinical Center of Serbia in Belgrade--building on the past (Q46471964) (← links)
- Evidence and Context of Use for Contrast Enhancement as a Surrogate of Disease Burden and Treatment Response in Malignant Glioma (Q47436703) (← links)
- Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach. (Q55472680) (← links)
- Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo (Q57291648) (← links)